Genprex Reports Promising Preclinical Data for Diabetes Gene Therapy GPX-002
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: NASDAQ.COM
- Therapeutic Efficacy: Genprex's diabetes gene therapy candidate GPX-002 demonstrated sustained improvements in glucose tolerance and reduced insulin requirements in non-human primate and mouse models, with one primate achieving normal glucose levels months post-treatment, indicating its potential to restore pancreatic cell function.
- Clinical Trial Plans: The company is continuing preclinical testing in Type 1 and Type 2 diabetes models and plans to advance GPX-002 toward human clinical trials, including toxicology studies and a future IND submission, paving the way for commercialization.
- Positive Market Reaction: Following the report, Genprex shares rose over 5% to close at $1.80, up 0.56%, reflecting investor confidence in the therapy's potential, which may drive future funding and R&D progress for the company.
- Strategic Development Direction: The positive preclinical data not only enhances the market appeal of GPX-002 but may also support Genprex's long-term strategic development in the diabetes treatment space, helping it secure a foothold in the competitive biopharmaceutical market.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like GNPX with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on GNPX
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Congressman Tim Moore Invests in Gene Therapy Company GNPX Amid High Volatility
- Investment Activity: Congressman Tim Moore made multiple purchases of shares in the gene therapy company Genprex (market cap under $5 million) in 2025, totaling between $31,000 and $115,000, indicating a keen interest in high-risk small-cap investments.
- Trading Performance: Moore was recognized as the top-performing member of Congress for stock trades in 2025, achieving a 52% return, significantly outperforming the S&P 500's 16.6% gain, which underscores the effectiveness of his investment strategy.
- Company Developments: Genprex experienced notable volatility in 2025, particularly in October when its stock surged following an update on its lead drug candidate REQORSA, highlighting market interest in its research progress.
- Future Outlook: Genprex plans to meet with the FDA to request Investigational New Drug studies, which could pave the way for human clinical trials, necessitating investor attention to the high volatility associated with its clinical data releases.
Continue Reading
Genprex Advances GPX-002 Diabetes Gene Therapy Clinical Program
- Clinical Progress: Genprex has reported encouraging early results from preclinical tests in mice and non-human primates, indicating that GPX-002 rejuvenates beta cells and normalizes glucose levels, marking a potential breakthrough in diabetes treatment.
- Manufacturing Transition: The company has moved the manufacturing of GPX-002 to skilled CDMO partners to enhance production capacity and optimize delivery methods, preparing for future human clinical trials and demonstrating a commitment to product quality and efficiency.
- FDA Meeting Plans: Genprex is seeking to meet with the FDA to discuss studies needed for an IND application, indicating a proactive approach in advancing clinical trials and a focus on regulatory compliance to expedite product market entry.
- Increased Research Investment: In 2025, the company plans to ramp up research efforts for Type 2 diabetes and initiate toxicology studies, further driving clinical trial advancements and showcasing its long-term commitment and strategic positioning in the diabetes treatment market.
Continue Reading